Weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients
- PMID: 15961776
- DOI: 10.1200/JCO.2004.01.0207
Weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients
Comment on
-
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.J Clin Oncol. 2004 Dec 1;22(23):4622-30. doi: 10.1200/JCO.2004.02.145. Epub 2004 Oct 25. J Clin Oncol. 2004. PMID: 15505276 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
